ArticleOncoTargets and therapy2019

Ultra-Low-Dose Bevacizumab For Cerebral Radiation Necrosis: A Prospective Phase II Clinical Study.

Hongqing Zhuang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.